JACC CARDIOVASC IMAGING 2021

Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis

Kim¹, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

FRONT ONCOL 2021 10.3389/fonc.2021.669817

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma

Lee¹, BH; Park, Y; Kim, JH; Kang, KW; Lee, SJ; Kim, SJ; Kim, BS

EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas

Yoon¹, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS

SCI REP-UK 2021 10.1038/s41598-021-89754-8

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma

Lee¹, JY; Kim, JH; Bang, H; Cho, J; Ko, YH; Kim, SJ; Kim, WS

KOREAN J INTERN MED 2021 10.3904/kjim.2019.367

Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia

Cho¹, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ

CANCER MANAG RES 2021 10.2147/CMAR.S309092

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

Lee¹, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ

ANN ONCOL 2021 10.1016/j.annonc.2020.12.009

Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial

Yhim¹, HY; Kim, T; Kim, SJ; Shin, HJ; Koh, Y; Kim, JS; Park, J; Park, GS; Kim, WS; Moon, JH; Yang, DH

SCI REP-UK 2021 10.1038/s41598-021-88815-2

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation

Park¹, YJ; Hyun, SH; Moon, SH; Lee, KH; Min, BH; Lee, JH; Kim, WS; Kim, SJ; Choi, JY

SCI REP-UK 2021 10.1038/s41598-021-85332-0

Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping

Lim¹, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS

FRONT ONCOL 2021 10.3389/fonc.2021.628807

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lee¹, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH

CANCER COMMUN 2021 10.1002/cac2.12150

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

Yi¹, JH; Kim, SJ; Yoon, DH; Suh, C; Chang, MH; Yang, DH; Jo, JC; Hyun, SY; Eom, HS; Lee, JO; Kwon, JH; Han, SH; Lee, SS; Kwak, JY; Kim, SH; Kim, DS; Lee, JH; Oh, SY; Ryoo, HM; Kim, HJ; Kim, WS

J CANCER 2021 10.7150/jca.55553

Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis

Lee¹, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ

J CANCER 2021 10.7150/jca.54434

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months

Yoon¹, SE; Cho, J; Kim, WS; Kim, SJ

SUPPORT CARE CANCER 2021 10.1007/s00520-021-06017-y

Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma

Kim¹, SJ; Kang, D; Park, Y; Mun, YC; Kim, K; Kim, JS; Min, CK; Cho, J

BMC CANCER 2021 10.1186/s12885-021-07806-8

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

Kang¹, JH; Lee, SH; Lee, J; Choi, M; Cho, J; Kim, SJ; Kim, WS; Ko, YH; Yoo, HY

CANCERS 2020 10.3390/cancers12123548

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma

Ryu¹, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ

BLOOD 2020

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma an open-label phase 2 study

Kim¹, SJ; Lim, JQ; Laurensia, Y; Cho, J; Yoon, SE; Lee, JY; Ryu, KJ; Ko, YH; Koh, Y; Cho, D; Lim, ST; Enemark, MB; D'amore, F; Bjerre, M; Ong, CK; Kim, WS

LEUKEMIA 2020 10.1038/s41375-020-01081-5

Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy

Jeong¹, SM; Choi, T; Kim, D; Han, K; Kim, SJ; Rhee, SY; Giovannucci, EL; Shin, DW

BONE MARROW TRANSPL 2020 10.1038/s41409-020-01160-2

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Song¹, GY; Yoon, DH; Suh, C; Moon, JH; Baek, DW; Kim, JS; Lee, GW; Yi, JH; Park, Y; Jung, KS; Kim, SJ; Yang, DH; Kim, WS

APPL IMMUNOHISTOCHEM MOL MORPHOL 2020 10.1097/PAI.0000000000000843

Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Cho¹, I; Yoon, N; Hyeon, J; Sim, J; Yoo, HY; Kim, SJ; Kim, WS; Ko, YH

BLOOD ADV 2020 10.1182/bloodadvances.2020002814

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Yhim¹, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R

BLOOD 2020 10.1182/blood.2020005026

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Kim¹, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS

ANN LAB MED 2020 10.3343/alm.2020.40.5.409

Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis

Yoo¹, IY; Bang, SH; Lim, DJ; Kim, SJ; Kim, K; Kim, HJ; Kim, SH; Cho, D

BMC CANCER 2020 10.1186/s12885-020-07317-y

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

Song¹, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ

LEUKEMIA 2020 10.1038/s41375-020-1000-0

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Lim¹, JQ; Huang, DC; Tang, T; Tan, D; Laurensia, Y; Peng, RJ; Wong, EKY; Cheah, DMZ; Chia, BKH; Iqbal, J; Grigoropoulos, NF; Nairismagi, ML; Ng, CCY; Rajasegaran, V; Hong, HM; Kim, SJ; Cho, J; Tse, E; Mow, B; Cai, QC; Poon, L; Cai, QQ; Tan, J; Chan, JY; Lim, JX; Goh, YT; Phipps, C; Rotzschke, O; Cheng, CL; Ha, JCH; Khoo, LP; Loh, YSM; Au-Yeung, R; Chan, TSY; Kwong, YL; Hwang, W; Kim, WS; Bei, JX; Lin, TY; Ong, CK; Lim, ST

CANCERS 2020 10.3390/cancers12082192

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis A Multicenter Phase 2 Trial

Yhim¹, HY; Yoon, DH; Kim, SJ; Yang, DH; Eom, HS; Ha Kim, K; Park, Y; Kim, JS; Kim, HJ; Suh, C; Kim, WS; Kwak, JY

PATIENT EDUC COUNS 2020 10.1016/j.pec.2020.03.007

Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners

Kim¹, IR; Jang, SY; Shin, HS; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Kim, SJ; Kim, K; Kim, WS; Lee, CH; Kang, D; Cho, J

SCI REP-UK 2020 10.1038/s41598-020-69616-5

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis developing a nomogram-based prognostic model

Lee¹, BH; Park, Y; Kim, JH; Kang, KW; Lee, SJ; Kim, SJ; Kim, BS

KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.396

Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system

Yoon¹, SE; Kim, WS; Kim, SJ

BMC CANCER 2020 10.1186/s12885-020-07102-x

Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization

Kang¹, KW; Lee, SJ; Kim, JH; Lee, BH; Kim, SJ; Park, Y; Kim, BS

SCI REP-UK 2020 10.1038/s41598-020-68310-w

Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era

Song¹, GY; Yoon, SE; Kim, SJ; Kim, JS; Koh, Y; Moon, JH; Oh, SY; Lee, HS; Shin, HJ; Do, YR; Lee, WS; Kim, DS; Park, Y; Yhim, HY; Yang, DH

ANN HEMATOL 2020 10.1007/s00277-020-04005-6

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Yoon¹, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04008-3

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas

Hur¹, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04083-6

A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study

Yoon¹, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ

CYTOKINE 2020 10.1016/j.cyto.2020.155048

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

Yi¹, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

ANN LAB MED 2020 10.3343/alm.2020.40.3.253

Isolation of Small Extracellular Vesicles From Human Serum Using a Combination of Ultracentrifugation With Polymer-Based Precipitation

Ryu¹, KJ; Lee, JY; Park, C; Cho, D; Kim, SJ

MODERN PATHOL 2020 10.1038/s41379-019-0392-8

Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression

Cho¹, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS

Lancet Haematol 2020 10.1016/S2352-3026(19)30283-2

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

Fox¹, CP; Civallero, M; Ko, YH; Manni, M; Skrypets, T; Pileri, S; Kim, SJ; Cabrera, ME; Shustov, AR; Chiattone, CS; Horwitz, SM; Dlouhy, I; Spina, M; Hitz, F; Montoto, S; Nagler, A; Martinez, V; De Souza, CA; Fernandez-Alvarez, R; Ballova, V; Gabus, R; Inghirami, G; Federico, M; Kim, WS

CANCER RES TREAT 2020 10.4143/crt.2019.198

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Kim¹, SJ; Yoon, DH; Kim, JS; Kang, HJ; Lee, HW; Eom, HS; Hong, JY; Cho, J; Ko, YH; Huh, J; Yang, WI; Park, WS; Lee, SS; Suh, C; Kim, WS

INVEST NEW DRUG 2020 10.1007/s10637-020-00916-3

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Kroschinsky¹, F; Middeke, JM; Janz, M; Lenz, G; Witzens-Harig, M; Bouabdallah, R; La Rosee, P; Viardot, A; Salles, G; Kim, SJ; Kim, TM; Ottmann, O; Chromik, J; Quinson, AM; von Wangenheim, U; Burkard, U; Berk, A; Schmitz, N

BLOOD ADV 2020 10.1182/bloodadvances.2019001114

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk

Witalis¹, M; Chang, J; Zhong, MC; Bouklouch, Y; Panneton, V; Li, JN; Buch, T; Kim, SJ; Kim, WS; Ko, YH; Veillette, A; Suh, WK

J HEMATOL ONCOL 2020 10.1186/s13045-020-00855-9

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

Yoon¹, DH; Cao, JN; Chen, TY; Izutsu, K; Kim, SJ; Kwong, YL; Lin, TY; Thye, LS; Xu, B; Yang, DH; Kim, WS

J AM COLL CARDIOL 2020 10.1016/j.jacc.2019.11.045

Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis

Choi¹, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES

PSYCHO-ONCOL 2020 10.1002/pon.5265

Impact of fear of cancer recurrence on survival among lymphoma patients

Kim¹, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J

CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-0694

Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion

Ryu¹, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY

BMC CANCER 2020 10.1186/s12885-020-6612-2

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Cho¹, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

ANN HEMATOL 2020 10.1007/s00277-019-03891-9

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma

Won¹, YW; Lee, H; Eom, HS; Kim, JS; Suh, C; Yoon, DH; Hong, JY; Kang, HJ; Lee, JH; Kim, WS; Kim, SJ; Lee, WS; Chang, MH; Do, YR; Yi, JH; Kim, I; Won, JH; Kim, K; Oh, SY; Jo, JC

ANN HEMATOL 2020 10.1007/s00277-019-03803-x

Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report

Jo¹, JC; Kim, SJ; Lee, HS; Eom, HS; Lee, SI; Park, Y; Lee, JO; Lee, Y; Yhim, HY; Yang, DH; Byun, JM; Kang, HJ; Kim, HJ; Shin, HJ; Yoo, KH; Suh, C

RESP MED 2020 10.1016/j.rmed.2019.105853

Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors

Im¹, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

MEDICINE 2020 10.1097/MD.0000000000018905

Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications

Lee¹, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY

KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.196

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance

Kim¹, HK; Kang, W; Sinn, DH; Lee, JH; Kim, WS; Kim, SJ

ANN LAB MED 2020 10.3343/alm.2020.40.1.88

Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults

Choi¹, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

AM J HEMATOL 2020 10.1002/ajh.25726

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Lee¹, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Lee¹, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

BMC CANCER 2019 10.1186/s12885-019-6303-z

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Kim¹, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

MEDICINE 2019 10.1097/MD.0000000000017641

Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study

Sim¹, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

ANN HEMATOL 2019 10.1007/s00277-019-03791-y

Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma

Yi¹, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

CANCER RES TREAT 2019 10.4143/crt.2018.555

Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma

Shin¹, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

INT J HEMATOL 2019 10.1007/s12185-019-02693-z

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores

Huh¹, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

J CLIN APHERESIS 2019 10.1002/jca.21734

Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma

Park¹, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

SCI REP-UK 2019 10.1038/s41598-019-51522-0

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study

Tan¹, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

ANN LAB MED 2019 10.3343/alm.2019.39.5.430

Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis

Park¹, MS; Yoo, IY; Kim, HJ; Kim, SH; Kim, SJ; Cho, D

Cancer Med 2019 10.1002/cam4.2347

Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma

Li Chan¹, EH; Koh, LP; Lee, J; De Mel, S; Jeyasekharan, A; Liu, X; Tang, T; Lim, ST; Tao, M; Quek, R; Ras, MFB; Lee, YS; Diong, C; Tan, D; Kim, SJ; Chee, YL; Poon, LM

SCI REP-UK 2019 10.1038/s41598-019-48513-6

Prognostic values of novel biomarkers in patients with AL amyloidosis

Kim¹, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016

A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study

Park¹, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1573998

Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes

Shin¹, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

SCI REP-UK 2019 10.1038/s41598-019-44245-9

Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis

Kim¹, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

CANCER RES TREAT 2019 10.4143/crt.2018.190

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma

Lee¹, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

CANCER RES TREAT 2019 10.4143/crt.2018.191

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Kim¹, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

BONE MARROW TRANSPL 2019 10.1038/s41409-018-0253-y

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing <= 70 kg

Kuruvilla¹, J; Tzeng, CH; Cho, SG; Kim, SJ; Tang, JL; Su, YM; Wu, JY; Vargo, R; Cheverton, P

ANN HEMATOL 2019 10.1007/s00277-018-3516-1

Validation of the Marginal Zone Lymphoma International Prognostic Index

Hong¹, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2018.1480772

Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma

Lim¹, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ

CYTOKINE 2019 10.1016/j.cyto.2018.10.009

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma

Yi¹, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.07.034

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Jeong¹, SH; Song, HN; Park, JS; Yang, DH; Koh, Y; Yoon, SS; Lee, HW; Eom, HS; Won, JH; Kim, WS; Kim, SJ

CANCER SCI 2018 10.1111/cas.13844

Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma

Kim¹, SJ; Shu, C; Ryu, KJ; Kang, D; Cho, J; Ko, YH; Lee, SY; Guallar, E; Zhao, W; Kim, WS

ANN HEMATOL 2018 10.1007/s00277-018-3442-2

The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms

Hwang¹, HS; Yoon, DH; Hong, JY; Park, CS; Lee, YS; Ko, YH; Kim, SJ; Kim, WS; Suh, C; Huh, J

EUR J NUCL MED MOL I 2018 10.1007/s00259-018-4093-1

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score

Yhim¹, HY; Park, Y; Han, YH; Kim, S; Kang, SR; Moon, JH; Jeong, JH; Shin, HJ; Kim, K; Choi, YS; Kim, K; Kim, MK; Kong, E; Kim, DS; Eo, JS; Lee, JH; Kang, DY; Lee, WS; Lee, SM; Do, YR; Ham, JS; Kim, SJ; Kim, WS; Choi, JY; Yang, DH; Kwak, JY

J CLIN MICROBIOL 2018 10.1128/JCM.00438-18

Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients

Ryu¹, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES

CANCER RES TREAT 2018 10.4143/crt.2017.207

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study

Kang¹, D; Cho, J; Kim, IR; Kim, MK; Kim, WS; Kim, SJ

INVEST NEW DRUG 2018 10.1007/s10637-018-0582-0

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Cho¹, H; Yoon, DH; Kim, KP; Bae, KS; Kim, WS; Eom, HS; Kim, JS; Hong, JY; Kim, SJ; Lee, H; Kim, SJ; Suh, C

ANN HEMATOL 2018 10.1007/s00277-018-3387-5

Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study

Oh¹, SY; Kim, WS; Kang, HJ; Lee, JH; Huh, S; Kim, S; Yoon, DH; Hong, JY; Lee, WS; Kim, HJ; Won, JH; Park, BB; Lee, SI; Suh, C

MODERN PATHOL 2018 10.1038/s41379-018-0064-0

Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement

Hyeon¹, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH

GENOME RES 2018 10.1101/gr.228080.117

Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data

Fan¹, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV

ANN HEMATOL 2018 10.1007/s00277-018-3317-6

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Hong¹, JY; Yoon, DH; Suh, C; Kim, WS; Kim, SJ; Jo, JC; Kim, JS; Lee, WS; Oh, SY; Park, Y; Kim, SY; Lee, MH; Lee, HS; Do, YR

ANN HEMATOL 2018 10.1007/s00277-018-3313-x

Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma

Cho¹, J; Kim, SJ; Park, S; Yoo, KH; Ki, CS; Ko, Y; Kim, WS

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5

Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study

Yoo¹, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

ANTICANCER RES 2018 10.21873/anticanres.12679

The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker

Kang¹, KW; Jung, JH; Hur, W; Park, J; Shin, H; Choi, B; Jeong, H; Kim, DS; Yu, ES; Lee, SR; Sung, HJ; Kim, SJ; Choi, CW; Kim, HK; Hong, S; Park, JH; Choi, Y; Park, Y; Kim, BS

BRIT J HAEMATOL 2018 10.1111/bjh.14701

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System

Jung¹, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ

CANCER SCI 2018 10.1111/cas.13597

Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

Yamaguchi¹, M; Suzuki, R; Kim, SJ; Ko, YH; Oguchi, M; Asano, N; Miyazaki, K; Terui, Y; Kubota, N; Maeda, T; Kobayashi, Y; Amaki, J; Soejima, T; Saito, B; Shimoda, E; Fukuhara, N; Tsukamoto, N; Shimada, K; Choi, I; Utsumi, T; Ejima, Y; Kim, WS; Katayama, N

CANCER RES TREAT 2018 10.4143/crt.2017.182

Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell

Lee¹, GI; Oh, D; Kim, WS; Kim, SJ; Ko, YH; Woo, KI; Kim, YD; Ahn, YC

HUM PATHOL 2018 10.1016/j.humpath.2017.12.006

Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay

Takayama¹, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH

Blood Cancer J 2018 10.1038/s41408-018-0056-9

CXCR4 can induce PI3K delta inhibitor resistance in ABC DLBCL

Kim¹, JH; Kim, WS; Ryu, KJ; Kim, SJ; Park, C

PLoS One 2018 10.1371/journal.pone.0192656

Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma

Kang¹, KW; Lee, SR; Kim, DS; Yu, ES; Sung, HJ; Kim, SJ; Choi, CW; Park, Y; Kim, BS

CANCER RES TREAT 2018 10.4143/crt.2017.091

Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors

Cho¹, J; Kang, D; Kim, IR; Kim, WS; Ferrell, B; Kim, SJ

ANN ONCOL 2018 10.1093/annonc/mdx684

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma

Kwong¹, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d'Amore, F; Schmitz, N; Jaccard, A; Kim, WS

HEMATOL ONCOL 2017 10.1002/hon.2374

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

HEMATOL ONCOL 2017 10.1002/hon.2374

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

Blood Cancer J 2017 10.1038/s41408-017-0030-y

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers

Tang¹, T; Khoo, LP; Lim, C; Ham, JS; Kim, SJ; Hong, HM; Phipps, C; Lee, YS; Tao, M; Quek, R; Farid, M; Lin, TY; Kim, WS; Lim, ST

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120

Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy

Park¹, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

ONCOTARGET 2017 10.18632/oncotarget.20988

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma

Hong¹, J; Kim, SJ; Chang, MH; Kim, JA; Kwak, JY; Kim, JS; Yoon, DH; Lee, WS; Do, YR; Kang, HJ; Eom, HS; Park, Y; Won, JH; Mun, YC; Kim, HJ; Kwon, JH; Kong, JH; Oh, SY; Lee, S; Bae, SH; Yang, DH; Jun, HJ; Lee, HS; Yun, HJ; Lee, SI; Kim, MK; Yi, JH; Lee, JH; Kim, WS; Suh, C

LANCET INFECT DIS 2017

Mycobacterium abscessus glossitis

Ko¹, JH; Kang, CI; Cho, SY; Ha, YE; Lee, NY; Kim, SJ; Chung, DR; Peck, KR; Song, JH

HEMATOL ONCOL 2017 10.1002/hon.2283

Macrophage inflammatory protein 1 alpha (MIP-1) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma

Kim¹, HS; Ryu, KJ; Ko, YH; Kim, HJ; Kim, SH; Kim, WS; Kim, SJ

ONCOTARGET 2017 10.18632/oncotarget.19301

Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma

Ham¹, JS; Park, HY; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

KOREAN JOURNAL OF INTERNAL MEDICINE 2017 10.3904/kjim.2015.406

Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea

Kim¹, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ

ANN ONCOL 2017 10.1093/annonc/mdx316

Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

Lim¹, SH; Hong, JY; Lim, ST; Hong, H; Arnoud, J; Zhao, W; Yoon, DH; Tang, T; Cho, J; Park, S; Ko, YH; Kim, SJ; Suh, C; Lin, T; Kim, WS

Leuk Lymphoma. 2017 Jun;58(6):1341-1348. doi: 10.1080/10428194.2016.1236380. Epub 2016 Oct 9.

Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma

Moon SH1¹, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.

Ann Hematol. 2017 May;96(5):739-747. doi: 10.1007/s00277-017-2940-y. Epub 2017 Feb 9.

Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life

Kim IR1¹, Kim SH2, Ok ON3, Kim SH4, Lee S5, Choi E6, Kim SJ7, Yoon DH8, Lee MH9.

Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase

Kwong YL1¹, Chan TSY1, Tan D2,3, Kim SJ4, Poon LM5, Mow B6, Khong PL7, Loong F8, Au-Yeung R8, Iqbal J9, Phipps C2,3, Tse E1.

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.

Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma

Kim HS1¹, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

Oncotarget. 2017 Mar 7;8(10):17038-17049. doi: 10.18632/oncotarget.14928.

The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP

Jung H1¹,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.

Psychooncology. 2017 Mar;26(3):330-336. doi: 10.1002/pon.4136. Epub 2016 Apr 13.

Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life

Kim SH1¹, Lee S2, Kim SH3, Ok ON4, Kim IR5, Choi E1, Kang YK6, Kim SJ7, Lee MH8.

Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm

Yoon N1¹, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.

Oncotarget. 2017 Feb 21;8(8):13782-13791. doi: 10.18632/oncotarget.14636.

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Hong JY1¹, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.

Bone Marrow Transplant. 2017 Feb;52(2):258-263. doi: 10.1038/bmt.2016.260. Epub 2016 Nov 7.

Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation

Lee MH1¹, Jang JH2, Min HJ3, Jang HI2, Nah JH2, Lyu CJ4, Han KS5, Won JH6, Lee YH7, Chong SY8, Mun YC9, Lee WS10, Kim SJ11, Kim I12.

Cancer Res Treat. 2017 Jan;49(1):92-103. doi: 10.4143/crt.2015.476. Epub 2016 May 9.

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma

Maeng CH1¹, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.

Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma

Ryu KJ1¹, Park C2, Hong M3, Ko YH4, Kim WS5, Kim SJ1,5.

ONCOTARGET, JAN 17 2017, 8(3):5361-5370, DOI: 10.18632/oncotarget.14243

Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappa B and Btk

Kim JH¹, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C

Mod Pathol. 2017 Jan;30(1):4-14. doi: 10.1038/modpathol.2016.56. Epub 2016 Sep 30.

Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression

Son SM1¹, Ha SY1, Yoo HY2,3, Oh D4, Kim SJ3,5, Kim WS3,5, Ko YH1,3.

Ann Lab Med. 2016 May;36(3):209-14. doi: 10.3343/alm.2016.36.3.209.

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma

Shin SY1¹,2, Lee ST2,3, Kim HJ2, Oh YL4, Kim SJ5, Kim WS5, Kim SH6.

Cancer Chemother Pharmacol. 2016 Apr;77(4):865-73. doi: 10.1007/s00280-016-3005-y. Epub 2016 Mar 16.

Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis

Shin DY1¹, Kim SJ2, Yoon DH3, Park Y4, Kong JH5, Kim JA6, Kim BS7, Kim HJ8, Won JH9, Park SK10, Kim WS11.

Ann Oncol. 2016 Mar;27(3):508-13. doi: 10.1093/annonc/mdv596. Epub 2015 Dec 9.

Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin

Kim SJ1¹, Kim JH2, Ki CS3, Ko YH4, Kim JS5, Kim WS6.

Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Kim SJ1¹, Yoon DH2, Jaccard A3, Chng WJ4, Lim ST5, Hong H6, Park Y7, Chang KM8, Maeda Y9, Ishida F10, Shin DY11, Kim JS12, Jeong SH13, Yang DH14, Jo JC15, Lee GW16, Choi CW17, Lee WS18, Chen TY19, Kim K20, Jung SH20, Murayama T21, Oki Y22, Advani R23, d'Amore F24, Schmitz N25, Suh C2, Suzuki R26, Kwong YL27, Lin TY6, Kim WS28.

Ann Hematol. 2016 Mar;95(4):581-91. doi: 10.1007/s00277-015-2581-y. Epub 2016 Jan 4.

Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability

Kim SM1¹, Park S1, Oh DR2, Ahn YC2, Ko YH3, Kim SJ1, Kim WS4.

Blood Cancer J. 2016 Feb 12;6:e395. doi: 10.1038/bcj.2016.2.

The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma

Ham JS1¹, Kim SJ1, Choi JY2, Hyun SH2, Choi SK3, Kim HS1, Lim SH1, Lee JY1, Jung SH3, Ko YH4, Kim WS1.

Oncotarget. 2016 Dec 27;7(52):86433-86445. doi: 10.18632/oncotarget.13239.

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma

Park HY1¹,2, Lee SB3, Yoo HY4, Kim SJ5, Kim WS5, Kim JI1, Ko YH2.

Oncotarget. 2016 Dec 20;7(51):85584-85591. doi: 10.18632/oncotarget.11319.

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)

Yoon DH1¹, Kim SJ2, Jeong SH3, Shin DY4, Bae SH5, Hong J6, Park SK7, Yhim HY8, Yang DH9, Lee H10, Kang HJ11, Lee MH12, Eom HS10, Kwak JY8, Lee JH6, Suh C1, Kim WS2.

Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study

Kim SJ1¹, Hong JS2, Chang MH3, Kim JA4, Kwak JY5, Kim JS6, Yoon DH7, Lee WS8, Do YR9, Kang HJ10, Eom HS11, Park Y12, Won JH13, Mun YC14, Kim HJ15, Kwon JH16, Kong JH17, Oh SY18, Lee S19, Bae SH20, Yang DH21, Jun HJ22, Kim YS23, Yun HJ24, Lee SI25, Kim MK26, Park EK27, Kim WS1, Suh C7.

Int J Hematol. 2016 Nov;104(5):591-595. Epub 2016 Jul 25.

Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kim WS4.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era

Seo S1¹, Hong JY1, Yoon S1,2, Yoo C1, Park JH1, Lee JB3, Park CS4, Huh J5, Lee Y5, Kim KW6, Ryu JS7, Kim SJ8, Kim WS8, Yoon DH1, Suh C1.

Ann Oncol. 2016 Nov;27(11):2133-2134. Epub 2016 Aug 8.

Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.

Kim SJ1¹,2, Kim WS3.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029.

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis

Kim SJ1¹, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.

Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10.

Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis

Lim SH1¹, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

Cancer Res Treat. 2016 Jan;48(1):312-21. doi: 10.4143/crt.2014.266. Epub 2015 Mar 2.

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism

Lim SH1¹, Woo SY2, Kim S2, Ko YH3, Kim WS1, Kim SJ1.

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.

Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

Acta Haematol. 2016;136(3):186-90. doi: 10.1159/000448159. Epub 2016 Sep 14.

Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma

Song HN1¹, Kim SJ, Ko YH, Kim WS.

BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

Jung SH1¹, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).

Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478.

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker

Ryu D1¹,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.

Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8.

Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL

Lim SH1¹, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

Haematologica. 2016 Jun;101(6):757-63. doi: 10.3324/haematol.2015.139253. Epub 2016 Jan 27.

Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma

Yoo HY1¹, Kim P2, Kim WS3, Lee SH4, Kim S5, Kang SY6, Jang HY7, Lee JE7, Kim J8, Kim SJ3, Ko YH9, Lee S10.

Leuk Lymphoma. 2016;57(6):1413-22. doi: 10.3109/10428194.2015.1113276. Epub 2015 Dec 24.

CD79B limits response of diffuse large B cell lymphoma to ibrutinib

Kim JH1¹, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.

Haematologica. 2016 Jun;101(6):e271. doi: 10.3324/haematol.2016.148015. Epub 2016 May 31.

Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

Yoo HY1¹, Kim P2, Kim WS3, Lee SH1, Kim S4, Kang SY5, Jang HY6, Lee JE6, Kim J7, Kim SJ3, Ko YH8, Lee S9.

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

Maeng CH1¹,2, Ahn SW3, Ryu SY3, Han S3, Ko YH4, Ji JH5, Kim WS2, Kim SJ2.

Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6.

The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea

Lee HS1¹, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14

Mod Pathol. 2016 May;29(5):430-43. doi: 10.1038/modpathol.2016.47. Epub 2016 Mar 25.

Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior

Hong M1¹,2, Lee T1, Young Kang S1, Kim SJ3, Kim W3, Ko YH1.

J Hematol Oncol. 2016 Apr 18;9:41. doi: 10.1186/s13045-016-0271-4.

L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kang ES4, Kim WS5.

Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Shin DY2, Kim JS3, Yoon DH4, Lee WS5, Lee H6, Do YR7, Kang HJ2, Eom HS6, Ko YH8, Lee SH9, Yoo HY10, Hong M11, Suh C4, Kim WS12.

Oncotarget. 2016 Mar 15;7(11):12359-71. doi: 10.18632/oncotarget.7132.

Clonal relationships in recurrent B-cell lymphomas

Lee SE1¹, Kang SY2, Yoo HY3, Kim SJ4, Kim WS4, Ko YH2.

Curr Opin Oncol. 2015 Sep;27(5):392-8. doi: 10.1097/CCO.0000000000000210.

Epstein - Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update

Hong JY1¹, Ko YH, Kim SJ, Kim WS.

Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.

KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

Acta Haematol. 2015;133(2):179-82. doi: 10.1159/000362149. Epub 2014 Oct 11.

Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma

Yoo KH1¹, Lee JY, Lim SH, Ko YH, Kim SJ, Kim WS.

Int J Hematol. 2015 Dec;102(6):678-88.

Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement

Lee MY¹, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim SJ, Kim WS.

Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Park S1¹, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

Haematologica. 2015 Dec;100(12):e505-7. doi: 10.3324/haematol.2015.133074. Epub 2015 Sep 24.

A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

Lee SH1¹, Kim JS1, Kim J2, Kim SJ3, Kim WS3, Lee S2, Ko YH4, Yoo HY5.

Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12.

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy

Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):677-83. doi: 10.1016/j.ijrobp.2015.07.2267. Epub 2015 Jul 22.

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Oh D1¹, Ahn YC2, Kim SJ3, Kim WS3, Ko YH4.

J Clin Lab Anal. 2015 Nov;29(6):505-10. doi: 10.1002/jcla.21801. Epub 2014 Oct 2.

Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma

Shin SY1¹, Lee ST1, Kim HJ1, Kim SJ2, Kim K2, Kang ES1, Kim SH1.

Leuk Lymphoma. 2015;56(11):3052-7. doi: 10.3109/10428194.2015.1025391. Epub 2015 Apr 8.

A subset of CD45+/CD19-cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma

Kim SM1¹, Lee ST2,3, Ryu KJ4, Kim HJ2, Kim SH2, Ko YH5, Kim WS1, Kim SJ1,6.

Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study

Koh MS1¹, Kim WS2, Kim SJ2, Oh SY3, Yoon DH4, Lee SI5, Hong J6, Song MK7, Shin HJ7, Kwon JH8, Kim HJ8, Do YR9, Suh C10, Kim HJ1.

Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26.

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

Park S1¹, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

Int Forum Allergy Rhinol. 2015 Oct;5(10):960-6. doi: 10.1002/alr.21564. Epub 2015 Jun 3.

Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

Cho HJ1¹, Jang MS2, Hong SD2, Kim SJ3, Ahn YC4, Oh D4, Ko YH5, Kim HY2, Dhong HJ2, Chung SK2, Kim WS3.

Ann Lab Med. 2015 Jan;35(1):149-51. doi: 10.3343/alm.2015.35.1.149. Epub 2014 Dec 8.

Simultaneous Occurrence of Angioimmunoblastic T-cell Lymphoma and Plasma Cell Leukemia

Jang MA1¹, Lee ST1, Kim HJ1, Kim S2, Kim SH1.

Ann Hematol. 2015 Sep;94(9):1485-92. doi: 10.1007/s00277-015-2389-9. Epub 2015 May 6.

Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines

Kim DS1¹, Kang KW, Lee SR, Park Y, Sung HJ, Kim SJ, Choi CW, Kim BS.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604. doi: 10.1016/j.bbmt.2015.05.003. Epub 2015 May 8.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Yhim HY1¹, Kim JS2, Mun YC3, Moon JH4, Chae YS4, Park Y5, Jo JC6, Kim SJ7, Yoon DH8, Cheong JW2, Kwak JY1, Lee JJ9, Kim WS7, Suh C8, Yang DH10; Consortium for Improving Survival of Lymphoma Study.

Cancer Res Treat. 2015 Jul;47(3):448-57. doi: 10.4143/crt.2014.034. Epub 2014 Nov 3.

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

Park S1¹, Kang CI2, Chung DR2, Peck KR2, Kim WS1, Kim SJ1.

Korean J Intern Med. 2015 Jul;30(4):496-505. doi: 10.3904/kjim.2015.30.4.496. Epub 2015 Jun 29.

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience

Lim AY1¹, Lee JH1, Jung KS1, Gwag HB1, Kim do H1, Kim SJ1, Lee GY1, Kim JS2, Kim HJ3, Lee SY3, Lee JE1, Jeon ES1, Kim K1.

Oncotarget. 2015 Jul 10;6(19):17764-76.

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

Lee S1¹, Park HY2, Kang SY3, Kim SJ4, Hwang J2, Lee S5, Kwak SH6, Park KS6,7, Yoo HY5, Kim WS4, Kim JI1,2,8, Ko YH3.

Genes Chromosomes Cancer. 2015 Jun;54(6):383-96. doi: 10.1002/gcc.22249. Epub 2015 Mar 31.

Integrated Copy Number and Gene Expression Profiling Analysis of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma

Yoon H1¹, Park S, Ju H, Ha SY, Sohn I, Jo J, Do IG, Min S, Kim SJ, Kim WS, Yoo HY, Ko YH.

Anticancer Res. 2015 Jun;35(6):3333-40.

Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma

Lim do H1¹, Kim WS2, Kim SJ3, Yoo HY4, Ko YH5.

J Hematol Oncol. 2015 May 14;8:49. doi: 10.1186/s13045-015-0142-4.

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients

Kim SJ1¹,2, Ryu KJ3, Hong M4, Ko YH5, Kim WS6.

Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20.

Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma

Lee GW1¹, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; Consortium for Improving Survival of Lymphoma (CISL) study group.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12.

The t(11;14)(q13;q32) Trans location as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma

Shin HJ1¹, Kim K2, Lee JJ3, Song MK1, Lee EY4, Park SH4, Kim SH5, Jang MA5, Kim SJ6, Chung JS1.

Anticancer Res. 2015 Apr;35(4):2465-74.

The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma

Hong JY1¹, Hong ME2, Choi MK3, Chang W4, Do IG5, Jo JS5, Jung SH6, Park S7, Kim SJ7, Ko YH2, Kim WS8.

Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28.

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

Hong J1¹, Kim SJ2, Ahn JS3, Song MK4, Kim YR5, Lee HS6, Yhim HY7, Yoon DH8, Kim MK9, Oh SY10, Park Y11, Mun YC12, Do YR13, Ryoo HM14, Lee JJ3, Lee JH1, Kim WS2, Suh C8.

Ann Hematol. 2015 Apr;94(4):617-25. doi: 10.1007/s00277-014-2258-y. Epub 2014 Dec 3.

Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation

Jeong SH1¹, Moon JH, Kim JS, Yang DH, Park Y, Cho SG, Kwak JY, Eom HS, Won JH, Hong JS, Oh SY, Lee HS, Kim SJ.

Int J Hematol. 2015 Mar;101(3):273-8. doi: 10.1007/s12185-014-1728-2. Epub 2015 Jan 1.

Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea

Kim MJ1¹, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS.

Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4.

EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity

Hong JY1¹, Yoon DH2, Suh C2, Huh J3, Do IG4, Sohn I4, Jo J4, Jung SH5, Hong ME6, Yoon H6, Ko YH6, Kim SJ7, Kim WS8.

Haematologica. 2015 Mar;100(3):e106-9. doi: 10.3324/haematol.2014.116087. Epub 2014 Dec 5.

Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator

Kim SJ1¹, Hong M2, Do IG2, Lee SH3, Ryu KJ4, Yoo HY5, Hong JY6, Ko YH2, Kim WS7.

Ann Hum Genet. 2015 Mar;79(2):99-107. doi: 10.1111/ahg.12101. Epub 2015 Jan 23.

Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis

Jang MA1¹, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES.

Ann Hematol. 2015 Jan;94(1):71-8. doi: 10.1007/s00277-014-2171-4. Epub 2014 Aug 2.

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients

Kim SJ1¹, Park S, Kang ES, Choi JY, Lim do H, Ko YH, Kim WS.

Onco Targets Ther. 2014 Sep 26;7:1717-22. doi: 10.2147/OTT.S67380. eCollection 2014.

Brentuximab vedotin for relapsed or refractory CD30+Hodgkin lymphoma: a multicenter analysis from Asia

Yang QM1¹, Hong JY2, Ko YH3, Lin SY4, Au WY4, Choi MK5, Park S6, Kim SJ6, Kim WS6.

Anticancer Res. 2014 Aug;34(8):4299-306.

Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement

Park S1¹, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10.

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Kim SM1¹, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Mayo Clin Proc. 2014 Jun;89(6):781-9. doi: 10.1016/j.mayocp.2014.01.013. Epub 2014 Apr 3.

Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness

Lee GY1¹, Kim K2, Choi JO1, Kim SJ2, Kim JS3, Choe YH4, Grogan MA5, Jeon ES6.

Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.

Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients

Park S1¹, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

Nat Genet. 2014 Apr;46(4):371-5. doi: 10.1038/ng.2916. Epub 2014 Mar 2.

A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma

Yoo HY1¹, Sung MK2, Lee SH3, Kim S4, Lee H4, Park S5, Kim SC5, Lee B5, Rho K6, Lee JE6, Cho KH7, Kim W4, Ju H8, Kim J4, Kim SJ9, Kim WS9, Lee S4, Ko YH10.

Br J Haematol. 2014 Mar;164(5):745-8. doi: 10.1111/bjh.12670. Epub 2013 Nov 18.

Central nervous system multiple myeloma: a different cytogenetic profile

Chang WJ1¹, Kim SJ, Kim K.

Hum Pathol. 2014 Mar;45(3):556-64. doi: 10.1016/j.humpath.2013.10.023. Epub 2013 Oct 31.

CD798 and MYD88 mutations in diffuse Large B-cell Lymphoma

Kim Y1¹, Ju H2, Kim DH3, Yoo HY4, Kim SJ5, Kim WS5, Ko YH6.

Anticancer Res. 2014 Feb;34(2):1037-45.

Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia

Jung HA1¹, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

Amyloid. 2014 Dec;21(4):261-6. doi: 10.3109/13506129.2014.960560. Epub 2014 Sep 24.

Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis

Lee JY1¹, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study

Kim SJ1¹, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS.

Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14.

Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma

Shin HJ1¹, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.

Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.

Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience

Lee KH1¹, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Support Care Cancer. 2014 Oct;22(10):2669-75. doi: 10.1007/s00520-014-2256-6. Epub 2014 Apr 26.

Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients

Cho J1¹, Kang D, Lee JY, Kim K, Kim SJ.

Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7.

Spinal cord compression in multiple myeloma: a single center experience

Jung HA1¹, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

Ann Hematol. 2014 Jan;93(1):113-21. doi: 10.1007/s00277-013-1893-z. Epub 2013 Sep 12.

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients

Kim K1¹, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16.

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

Park S1¹, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

Cancer Res Treat. 2014 Jan;46(1):104-7. doi: 10.4143/crt.2014.46.1.104. Epub 2014 Jan 15.

Primary Follicular Lymphoma in a Male Breast: A Case Report

Jung SP1¹, Han KM2, Kim SJ3, Nam SJ4, Bae JW1, Lee JE4.

Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases

Hong JY1¹, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Ann Hematol. 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3. Epub 2014 Apr 12.

Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study

Ahn SY1¹, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.

Leuk Lymphoma. 2014 Sep;55(9):2196-8. doi: 10.3109/10428194.2013.871279. Epub 2014 Feb 17.

Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma

Chang WJ1¹, Ko YH, Kim SJ, Kim WS.

Support Care Cancer. 2014 Aug;22(8):2039-48. doi: 10.1007/s00520-014-2174-7. Epub 2014 Mar 5.

Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy

Yoon YK1¹, Kim MJ, Sohn JW, Kim HS, Choi YJ, Kim JS, Kim ST, Park KH, Kim SJ, Kim BS, Shin SW, Kim YH, Park Y.

Acta Haematol. 2014;132(2):226-32.

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

Chang WJ¹, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.

Cancer Res Treat. 2014 Jul;46(3):307-11. doi: 10.4143/crt.2014.46.3.307. Epub 2014 Jul 15.

Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein

Ha JM1¹, Kim E, Lee WJ, Hwang JW, Yune S, Ko YH, Choi JY, Kim SJ, Kim WS.

Biomed Res Int. 2014;2014:245247. doi: 10.1155/2014/245247. Epub 2014 Jun 23.

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

Eom KS1¹, Kim SJ2, Lee JJ3, Suh C4, Kim JS5, Yoon SS6, Kim BS7, Kang HJ8, Choi YJ9, Kim CS10, Kim YS11, Kwak JY12, Kim YJ1, Joo YD13, Mun YC14, Jo DY15, Park JS16, Park CY17, Kim SH18, Min CK1.

Ann Hematol. 2014 Mar;93(3):437-47. doi: 10.1007/s00277-013-1884-0. Epub 2013 Aug 24.

Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay

Kim SJ1¹, Sohn I, Do IG, Jung SH, Ko YH, Yoo HY, Paik S, Kim WS.

Acta Haematol. 2014;131(3):156-61. doi: 10.1159/000353787. Epub 2013 Oct 31.

Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP

Kim YS1¹, Ji JH, Ko YH, Kim SJ, Kim WS.

Nutr Cancer. 2014;66(2):225-33. doi: 10.1080/01635581.2014.867065. Epub 2014 Jan 9.

Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP

Park S1¹, Han B, Cho JW, Woo SY, Kim S, Kim SJ, Kim WS.

Acta Haematol. 2014;131(1):18-27. doi: 10.1159/000351060. Epub 2013 Sep 10.

Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea

Hong JY1¹, Kim HJ, Ko YH, Choi JY, Jung CW, Kim SJ, Kim WS.

Invest New Drugs. 2013 Dec;31(6):1514-21. doi: 10.1007/s10637-013-0015-z. Epub 2013 Aug 24.

A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, Lee J, Yim DS, Lee SY, Park WS, Yang WI, Lee SS, Suh C, Kim WS.

Amyloid. 2013 Dec;20(4):204-11. doi: 10.3109/13506129.2013.824417. Epub 2013 Aug 5.

Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea

Kim SJ1¹, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Lancet Oncol. 2013 Nov;14(12):e548-61. doi: 10.1016/S1470-2045(13)70450-9.

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

Tan D1¹, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL.

Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

Kim SJ1¹, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

J Hematol Oncol. 2013 Nov 16;6:86. doi: 10.1186/1756-8722-6-86.

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Kim SJ1¹, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS; Asia Lymphoma Study Group.

Int J Hematol. 2013 Sep;98(3):346-54. doi: 10.1007/s12185-013-1403-z. Epub 2013 Jul 19.

Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation

Choi MK1¹, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS.

Ann Hematol. 2013 Aug;92(8):1101-10. doi: 10.1007/s00277-013-1728-y. Epub 2013 Apr 5.

Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia

Lee SM1¹, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party.

J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6.

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ohmachi K1¹, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M.

Jpn J Clin Oncol. 2013 Jun;43(6):676-80. doi: 10.1093/jjco/hyt047. Epub 2013 Apr 5.

Unusual Presentation of Ewing Sarcoma in the Adrenal Gland: A Secondary Malignancy from a Survivor of Burkitt Lymphoma

Lim SH1¹, Lee JY, Lee JY, Kim JH, Choi KH, Hyun JY, Ko YH, Lee J, Kim SJ, Kim WS.

Acta Haematol. 2013;129(1):10-7. doi: 10.1159/000341284. Epub 2012 Sep 8.

Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas

Lee MR1¹, Ju HJ, Kim BS, Ko YH, Kim WS, Kim SJ.

Int J Hematol. 2012 Nov;96(5):631-7. doi: 10.1007/s12185-012-1200-0. Epub 2012 Oct 12.

Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal A study by the Consortium for Improving Survival of Lymphoma (CISL)

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ.

Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

Kim SJ1¹, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators.

Ann Hematol. 2012 Nov;91(11):1747-56. doi: 10.1007/s00277-012-1516-0. Epub 2012 Jun 28.

Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

Jung HA1¹, Park S, Cho JH, Kim S, Ko YH, Kim SJ, Kim WS.

Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group

Kwong YL1¹, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS.

Thromb Res. 2012 Sep;130(3):e6-12. doi: 10.1016/j.thromres.2012.03.019. Epub 2012 Apr 14.

Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population

Park LC1¹, Woo SY, Kim S, Jeon H, Ko YH, Kim SJ, Kim WS.

Leuk Lymphoma. 2012 Aug;53(8):1515-24. doi: 10.3109/10428194.2012.659735. Epub 2012 Mar 1.

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

Kim SJ1¹, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL, Kim WS, Kwong YL.

J Hematol Oncol. 2012 Aug 13;5:49.

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Kim YR1¹, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, Kim WS, Suh C.

Am J Hematol. 2012 Jul;87(7):663-8. doi: 10.1002/ajh.23213. Epub 2012 May 28.

Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group

Tse E1¹, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, Kim WS, Kwong YL.

Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30.

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy

Yhim HY1¹, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.

Leuk Lymphoma. 2012 May;53(5):807-11. doi: 10.3109/10428194.2011.635857. Epub 2011 Dec 7.

Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma

Yang DH1¹, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh C, Lee JJ.

Acta Haematol. 2012;127(3):129-34. doi: 10.1159/000333139. Epub 2012 Jan 12.

Endoscopic Findings in Mantle Cell Lymphoma with Gastrointestinal Tract Involvement

Kim JH1¹, Jung HW, Kang KJ, Min BH, Lee JH, Chang DK, Kim YH, Son HJ, Rhee PL, Kim JJ, Rhee JC, Kim SJ, Kim WS, Ko YH, Kim JY.

Acta Haematol. 2012;127(2):100-4. doi: 10.1159/000333113. Epub 2011 Dec 15.

Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease - Consortium for Improving Survival of Lymphoma Study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Kang HJ, Song MK, Kim HJ, Kwon JH, Kwak JY, Park BB, Do YR, Jeong SH, Suh C.

Invest New Drugs. 2012 Feb;30(1):368-75. doi: 10.1007/s10637-010-9523-2. Epub 2010 Aug 24.

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Kim SJ1¹, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, Kim WS.

Ann Hematol. 2012 Feb;91(2):223-33. doi: 10.1007/s00277-011-1297-x. Epub 2011 Jul 26.

Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Won YW1¹, Kwon JH, Lee SI, Oh SY, Kim WS, Kim SJ, Won JH, Kim KH, Park SK, Kim JS, Suh C, Yoon DH, Park JS, Kim MK, Kim H, Kang HJ, Mun YC, Kwak JY, Kim HJ, Eom HS.

Leuk Lymphoma. 2012 Jan;53(1):19-25. doi: 10.3109/10428194.2011.603448. Epub 2011 Sep 6.

B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy

Kim SJ1¹, Won JH.

Leuk Lymphoma. 2012 Jan;53(1):173-5. doi: 10.3109/10428194.2011.608452. Epub 2011 Sep 23.

Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value

Lee HY¹, Kim SJ, Kim K, Ko YH, Kim WS.

Acta Haematol. 2011;126(2):79-86. doi: 10.1159/000327255. Epub 2011 May 4.

Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma

Park Y1¹, Choi YJ, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW, Jung KY, Kim BS.

J Hematol Oncol. 2011 Aug 15;4:34. doi: 10.1186/1756-8722-4-34.

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Kim YR1¹, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH.

BMC Cancer. 2011 Jul 29;11:321. doi: 10.1186/1471-2407-11-321.

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

Kim SJ1¹, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS.

Ann Hematol. 2011 May;90(5):539-46. doi: 10.1007/s00277-010-1104-0. Epub 2010 Oct 20.

Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma

Kim SJ1¹, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C.

Jpn J Clin Oncol. 2011 Mar;41(3):353-7. doi: 10.1093/jjco/hyq194. Epub 2010 Oct 14.

Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study

Kim SJ1¹, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.

Ann Oncol. 2011 Feb;22(2):411-6. doi: 10.1093/annonc/mdq393. Epub 2010 Aug 2.

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients

Kim MK1¹, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.

Blood. 2011 Feb 10;117(6):1958-65. doi: 10.1182/blood-2010-06-288480. Epub 2010 Dec 9.

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone

Kim SJ1¹, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS.

Leuk Lymphoma. 2011 Feb;52(2):317-20. doi: 10.3109/10428194.2010.529203. Epub 2010 Nov 11.

Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy

Yi JH¹, Kim SJ, Ko YH, Kim WS.

Leuk Lymphoma. 2011 Feb;52(2):205-13. doi: 10.3109/10428194.2010.542261.

Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis

Kim JA1¹, Kim SJ, Do IG, Jin J, Nam DH, Ko YH, Kim K, Kim WS.

Cancer Genet Cytogenet. 2010 Dec;203(2):215-21. doi: 10.1016/j.cancergencyto.2010.08.022.

GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization

Koh Y1¹, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S.

Jpn J Clin Oncol. 2010 Dec;40(12):1147-53. doi: 10.1093/jjco/hyq111. Epub 2010 Jul 20.

Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients

Seo HY1¹, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS.

Int J Hematol. 2010 Dec;92(5):690-6. doi: 10.1007/s12185-010-0720-8. Epub 2010 Nov 18.

Treatment of localized extranodal NK/T cell lymphoma, nasal type

Kim SJ1¹, Kim WS.

Cancer Sci. 2010 Nov;101(11):2443-7. doi: 10.1111/j.1349-7006.2010.01698.x.

Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ.

J Bone Miner Metab. 2010 Nov;28(6):713-8. doi: 10.1007/s00774-010-0203-2. Epub 2010 Jul 6.

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate

Yang KH1¹, Park SY, Park SW, Lee SH, Han SB, Jung WK, Kim SJ.

Haematologica. 2010 Nov;95(11):1935-42. doi: 10.3324/haematol.2010.026104. Epub 2010 Jul 27.

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

Kim SJ1¹, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH.

Ann Hematol. 2010 Oct;89(10):1011-8. doi: 10.1007/s00277-010-0978-1. Epub 2010 May 7.

Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea

Won YW1¹, Kim SJ, Kim K, Ko YH, Kim WS.

Int J Hematol. 2010 Oct;92(3):510-7. doi: 10.1007/s12185-010-0680-z. Epub 2010 Sep 14.

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ.

Qual Life Res. 2010 Oct;19(8):1097-103. doi: 10.1007/s11136-010-9670-0. Epub 2010 May 5.

Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma

Kim BJ1¹, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, Cho SC, So YT, Oh SY, Kim SJ.

Leuk Res. 2010 Sep;34(9):1175-9. doi: 10.1016/j.leukres.2010.02.010. Epub 2010 Mar 5.

Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report

Yun J1¹, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, Kim MK, Kwak JY, Kim WS, Suh C.

Hematol Oncol. 2010 Jun;28(2):57-61. doi: 10.1002/hon.905.

F-18-FDG uptake and its clinical relevance in primary gastric lymphoma

Yi JH1¹, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS.

Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8.

A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Kim ST1¹, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321.

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Yhim HY1¹, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY.

Ann Oncol. 2010 May;21(5):1058-63. doi: 10.1093/annonc/mdp412. Epub 2009 Oct 22.

When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type

Kim SJ1¹, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS.

Am J Hematol. 2010 May;85(5):362-3. doi: 10.1002/ajh.21663.

Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission

Au WY¹, Kim SJ, Yiu HH, Ngan RK, Loong F, Kim WS, Kwong YL.

Int J Hematol. 2010 Apr;91(3):456-63. doi: 10.1007/s12185-010-0536-6. Epub 2010 Mar 3.

Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients

Ahn HK1¹, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS.

Bone Marrow Transplant. 2010 Apr;45(4):801-2. doi: 10.1038/bmt.2009.240. Epub 2009 Sep 21.

Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

Lee SC¹, Kim SJ, Lee DH, Kim WS, Suh C, Won JH.

Invest New Drugs. 2010 Apr;28(2):171-7. doi: 10.1007/s10637-009-9260-6. Epub 2009 May 7.

Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial

Oh SY1¹, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C.

Med Oncol. 2010 Mar;27(1):91-7. doi: 10.1007/s12032-009-9178-z. Epub 2009 Feb 24.

Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer

Kim SJ1¹, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ.

Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008.

Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia

Bang SM1¹, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).

Leuk Res. 2010 Mar;34(3):294-300. doi: 10.1016/j.leukres.2009.08.024. Epub 2009 Sep 16.

The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease

Park Y1¹, Kim DS, Park SJ, Seo HY, Lee SR, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.

Echocardiography. 2010 Feb;27(2):E23-6. doi: 10.1111/j.1540-8175.2009.01059.x.

Primary Angiosarcoma of the Pulmonary Trunk Mimicking Pulmonary Thromboembolism

Kim JB1¹, Kim SH, Lim SY, Roh SY, Cho GY, Song HJ, Park S, Lee J, Kim SJ.

Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25.

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

Koh Y1¹, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party.

J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16.

Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Choi ER1¹, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.

J Clin Oncol. 2009 Dec 10;27(35):6027-32. doi: 10.1200/JCO.2009.23.8592. Epub 2009 Nov 2.

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

Kim SJ1¹, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS.

Acta Haematol. 2010;123(1):48-54. doi: 10.1159/000262291. Epub 2009 Dec 2.

Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience

Yun J1¹, Kim SJ, Kim JA, Kong JH, Lee SH, Kim K, Ko YH, Kim WS.

Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29.

Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry

Kim SJ1¹, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

Ann Hematol. 2009 Nov;88(11):1099-106. doi: 10.1007/s00277-009-0729-3. Epub 2009 Mar 14.

Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea

Choi MK1¹, Jun HJ, Lee SY, Kim KH, Lim do H, Kim K, Ko YH, Kim WS, Kim SJ.

Leuk Lymphoma. 2009 Jul;50(7):1119-25. doi: 10.1080/10428190902926999.

Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea

Chang MH1¹, Kim SJ, Kim K, Oh SY, Lee DH, Huh J, Ko YH, Choi CW, Yang DH, Won JH, Kim WS, Suh C.

Cancer Res Treat. 2009 Jun;41(2):104-7. doi: 10.4143/crt.2009.41.2.104. Epub 2009 Jun 30.

Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy

Seo HY1¹, Kim EB, Kim JW, Shin BK, Kim SJ, Kim BS.

Med Oncol. 2009;26(1):45-8. doi: 10.1007/s12032-008-9079-6. Epub 2008 Jun 10.

Rituximab-induced acute thrombocytopenia: a case report and review of the literature

Yi JH1¹, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS.

Ann Oncol. 2009 Feb;20(2):390-2. doi: 10.1093/annonc/mdn726.

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

Kim SJ¹, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS.

Acta Haematol. 2008;120(4):211-6. doi: 10.1159/000193223. Epub 2009 Jan 20.

Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas

Kim SJ1¹, Lee SJ, Sung HJ, Choi IK, Choi CW, Kim BS, Kim JS, Yu W, Hwang HS, Kim IS.

Eur J Haematol. 2008 Sep;81(3):177-84. doi: 10.1111/j.1600-0609.2008.01099.x. Epub 2008 May 27.

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy

Kim SJ1¹, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS.

Clin Lymphoma Myeloma. 2008 Aug;8(4):237-40. doi: 10.3816/CLM.2008.n.031.

Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma

Kim SJ1¹, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, Nam SH, Kwon JH, Kim HJ, Sohn SK, Won JH, Lee JH, Suh C, Yoon SS, Kim HJ, Kim I, Do YR, Lee WS, Joo YD, Shin HJ; Korean Multiple Myeloma Working Party.

Leuk Lymphoma. 2008 Aug;49(8):1623-6. doi: 10.1080/10428190802129934.

Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: Does it have a prognostic value

Park Y¹, Kim SJ, Lee SJ, Kim BS.